Ricardo Iramain1,2, Jose A Castro-Rodriguez3, Alfredo Jara1, Laura Cardozo1, Norma Bogado1, Rocío Morinigo1, Raúl De Jesús1. 1. Division of Pediatrics, Emergency Department, Clinical Hospital, National University of Asunción, Asunción, Paraguay. 2. Emergency Department, Private Childreńs Institute Asunción, Asunción, Paraguay. 3. Division of Pediatrics, Department of Pediatric Respiratory and Cardiology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Abstract
INTRODUCTION: In moderate-severe asthma exacerbation, salbutamol by inhaler (MDI) is superior to salbutamol delivered by nebulizer (NEB); however, to our knowledge, no studies in children with exclusively severe exacerbations were performed. OBJECTIVE: To compare the efficacy of salbutamol and ipratropium bromide by MDI versus by NEB in severe asthma exacerbations. METHODS: We performed a clinical trial enrolling 103 children (2-14 years of age) with severe asthma exacerbations (defined by the Pulmonary Score ≥ 7) seen at the emergency room in Asuncion, Paraguay. One group received salbutamol and ipratropium (two puff every 10 min for 2 h and then every 30 min for 2 h more) by MDI with a valved-holding chamber and mask along with oxygen by a cannula separately (MDI-SIB); and the other received nebulization with oxygen (NEB-SIB) of salbutamol and ipratropium (1 every 20 min for 2 h and then every 30 min for 2 h more). Primary outcome was the rate of hospitalization (Pulmonary Score ≥ 7) after 4 h and secondary outcome was oxygen saturation. RESULTS: Fifty two children received MDI-SIB and 51 NEB-SIB. After the 4th hour, children on MDI-SIB had significantly (P = 0.003) lower rate of hospital admission than on NEB-SIB (5.8% vs 27.5%, RR: 0.21 [0.06-0.69], respectively). Similarly, a significant improved clinical score after 60 min and increase in oxygen saturation after 90 min of treatment was observed in MDI-SIB versus NEB-SIB group (4.46 ± 0.7 vs 5.76 ± 0.65, P < 0.00001; and 90.5 ± 1.7 vs 88.43 1 ± 1, P < 0.00001, respectively). CONCLUSION: Even in severe asthma exacerbations administration of salbutamol and ipratropium by MDI with valved-holding chamber and mask along with oxygen by a cannula separately was more effective than by a nebulizer.
RCT Entities:
INTRODUCTION: In moderate-severe asthma exacerbation, salbutamol by inhaler (MDI) is superior to salbutamol delivered by nebulizer (NEB); however, to our knowledge, no studies in children with exclusively severe exacerbations were performed. OBJECTIVE: To compare the efficacy of salbutamol and ipratropium bromide by MDI versus by NEB in severe asthma exacerbations. METHODS: We performed a clinical trial enrolling 103 children (2-14 years of age) with severe asthma exacerbations (defined by the Pulmonary Score ≥ 7) seen at the emergency room in Asuncion, Paraguay. One group received salbutamol and ipratropium (two puff every 10 min for 2 h and then every 30 min for 2 h more) by MDI with a valved-holding chamber and mask along with oxygen by a cannula separately (MDI-SIB); and the other received nebulization with oxygen (NEB-SIB) of salbutamol and ipratropium (1 every 20 min for 2 h and then every 30 min for 2 h more). Primary outcome was the rate of hospitalization (Pulmonary Score ≥ 7) after 4 h and secondary outcome was oxygen saturation. RESULTS: Fifty two children received MDI-SIB and 51 NEB-SIB. After the 4th hour, children on MDI-SIB had significantly (P = 0.003) lower rate of hospital admission than on NEB-SIB (5.8% vs 27.5%, RR: 0.21 [0.06-0.69], respectively). Similarly, a significant improved clinical score after 60 min and increase in oxygen saturation after 90 min of treatment was observed in MDI-SIB versus NEB-SIB group (4.46 ± 0.7 vs 5.76 ± 0.65, P < 0.00001; and 90.5 ± 1.7 vs 88.43 1 ± 1, P < 0.00001, respectively). CONCLUSION: Even in severe asthma exacerbations administration of salbutamol and ipratropium by MDI with valved-holding chamber and mask along with oxygen by a cannula separately was more effective than by a nebulizer.
Authors: Nikolaos G Papadopoulos; Adnan Custovic; Antoine Deschildre; Alexander G Mathioudakis; Wanda Phipatanakul; Gary Wong; Paraskevi Xepapadaki; Ioana Agache; Leonard Bacharier; Matteo Bonini; Jose A Castro-Rodriguez; Zhimin Chen; Timothy Craig; Francine M Ducharme; Zeinab Awad El-Sayed; Wojciech Feleszko; Alessandro Fiocchi; Luis Garcia-Marcos; James E Gern; Anne Goh; René Maximiliano Gómez; Eckard H Hamelmann; Gunilla Hedlin; Elham M Hossny; Tuomas Jartti; Omer Kalayci; Alan Kaplan; Jon Konradsen; Piotr Kuna; Susanne Lau; Peter Le Souef; Robert F Lemanske; Mika J Mäkelä; Mário Morais-Almeida; Clare Murray; Karthik Nagaraju; Leyla Namazova-Baranova; Antonio Nieto Garcia; Osman M Yusuf; Paulo M C Pitrez; Petr Pohunek; Cesar Fireth Pozo Beltrán; Graham C Roberts; Arunas Valiulis; Heather J Zar Journal: J Allergy Clin Immunol Pract Date: 2020-06-17